Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX

April 21, 2024 06:02 PM PDT | By Invezz

Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX — Image source: Invezz

Viking Therapeutics

Viking Therapeutics (NASDAQ: VKTX) stock price has surged by almost 200% in the past 12 months and by 240% this year. This surge has pushed its total market cap to almost $7 billion, making it one of the best-performing companies in the industry.

Viking Therapeutics has done well because of its weight loss drug that is now being studied. Its testing reports have shown that the drug leads to substantial weight loss, which is a positive thing.

Further, the company has a strong balance sheet with over $360 million in cash and just $1 million in debt. I believe that Viking may become a good takeover target as more large companies move to the weight loss industry. Most of the big pharma companies have seen the success of Novo Nordisk and Eli Lilly.

There is a risk, however, for investing in Viking. The biggest risk is that the drug fails in its testing. Also, there is a risk that it may not become a takeover target since the weight loss industry is becoming a duopoly.

Sana Biotechnology

Sana Biotechnology (NASDAQ: SANA) stock price has jumped by over 85% this year and by 36% in the past 12 months. That jump has pushed its total market cap to over $1.7 billion.

Sana Biotech is a company that is using cell engineering to create drugs for area like oncology, central nervous system, and diabetes. Its drugs include Ardent, Gleam, and Vivid.

The company’s science is quite complicated but analysts believe that it can change the treatment process if it works. For example, in Type 1 Diabetes, Sana Biotechnology aims to use cell engineering to give users stealthy new cells that can make insulin without being attacked.

The risk for investing in Sana Biotechnology is that it is burning substantial sums of money. It lost over $283 million in 2023 after losing $269 million in 2023. As such, since it has just $135 million in cash, there is a risk that it will raise additional funds.

The other risk is that most of the products in its pipeline are in the first stage of trial, meaning that things could go wrong.

Recursion Pharmaceuticals

Recursion Pharmaceuticals (NASDAQ: RXRX) stock price has jumped by over 23% in the past 12 months. It has dropped by over 25% this year but analysts believe that it has room to recover.

The company is working on products to treat rare conditions and oncology. Most of its products have moved to the second phase of trial, which is a positive thing. It has also used big data and artificial intelligence to accelerate drug discovery.

Recursion Pharmaceutical’s revenue is growing. It made over $44.6 million in 2023, up from $36 million a year earlier. However, the company is still losing substantial sums of money, opening it for potential dilution. It had a net loss of over $328 million in 2023 and has over $391 million in cash and short-term investments, meaning that it could dilute its investors this year.

The post Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.